Drugs / NEV801
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02797795 | Dec 2016 → Dec 2023 | cancer | Neovia Oncology Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEV801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02797795 ↗ |
| Route | Intravenous | “subjects will be treated with a 30-minute intravenous (IV) infusion of NEV801” NCT02797795 ↗ |